Theriva Biologics, Inc. filings document a Nevada clinical-stage biotechnology issuer with common stock listed on the NYSE American under TOVX. The company’s Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical and regulatory updates for VCN-01, and material-event disclosures tied to its oncology development programs.
Theriva Biologics proxy statements cover stockholder meeting mechanics, governance matters and shareholder approval proposals related to warrant exercises and potential common-stock issuance under NYSE American rules. Other 8-K disclosures record material definitive agreements, including the SYN-020 license arrangement, alongside capital-structure, voting and corporate-update information relevant to the company’s development-stage business.
Theriva Biologics, Inc. reported an equity award to its senior leadership. On 01/05/2026, a reporting person who serves as director, CEO and CFO received an option grant over 475,000 shares of common stock at an exercise price of $0.241 per share.
The stock options become exercisable on a pro rata monthly basis over 36 months, starting on 02/01/2026, and are scheduled to expire on 01/04/2033 if not exercised. Following this grant, the reporting person held 475,000 derivative securities directly, aligning a portion of their compensation with the company’s future share performance.
Theriva Biologics, Inc. director John J. Monahan reported a new stock option grant. On 01/05/2026 he received stock options to buy 75,000 shares of common stock at an exercise price of $0.241 per share. The options become exercisable starting 02/01/2026 and expire on 01/04/2033. They vest on a pro rata monthly basis over 12 months, which means a portion of the options becomes available to exercise each month during the first year.
Theriva Biologics, Inc. reported an insider equity award to one of its directors. The Form 4 shows a grant of 75,000 stock options with an exercise price of $0.241 per share on 01/05/2026. These options become exercisable starting 02/01/2026 and expire on 01/04/2033. According to the footnote, the options vest on a pro rata monthly basis over 12 months, meaning the director earns a portion of the grant each month during the first year.
Theriva Biologics, Inc. reported a new equity award to one of its directors. On 01/05/2026, the director received 75,000 stock options to purchase common stock at an exercise price of $0.241 per share. These options are classified as derivative securities and are held directly by the reporting person.
The options begin to vest on 02/01/2026 and expire on 01/04/2033. They vest on a pro rata monthly basis over 12 months, meaning the award is spread evenly across a one-year period. Following this grant, the reporting person beneficially owns 75,000 derivative securities linked to Theriva Biologics common stock.
Theriva Biologics is asking stockholders to approve the potential issuance of up to 16,184,560 shares of common stock upon exercise of new common stock purchase warrants issued to institutional investors in an October 17, 2025 private placement. If all these New Warrants are exercised for cash at the initial $0.54 exercise price, the company could receive up to approximately $8.7 million in gross proceeds, but existing holders would be diluted when the shares are issued. As of the December 31, 2025 record date, there were 35,688,349 shares of common stock outstanding. A second proposal would allow adjournment of the February 11, 2026 special meeting to gather additional votes if needed. The Board unanimously recommends voting “FOR” both proposals.
Theriva Biologics disclosed that it has received formal Scientific Advice from the European Medicines Agency’s CHMP on the design of a planned Phase 3 trial for its lead candidate VCN-01 in first-line metastatic pancreatic adenocarcinoma. The advice indicates that a potential future marketing authorization application could be supported by a single, double-blinded, randomized, placebo-controlled Phase 3 study if it shows a compelling benefit-risk profile for VCN-01 plus gemcitabine/nab-paclitaxel standard-of-care versus chemotherapy alone.
CHMP agreed with key trial elements, including inclusion and exclusion criteria, overall survival as the primary endpoint, several secondary endpoints such as progression free survival and duration of response, sample size, and the use of an adaptive design. The committee also acknowledged the improved overall survival seen with two doses of VCN-01 in the prior VIRAGE Phase 2b trial and agreed with a repeated “macrocycle” dosing schedule that allows more than two doses in Phase 3, while suggesting that even more frequent dosing could be considered.
Theriva Biologics is asking stockholders to approve the issuance of up to 16,184,560 shares of common stock upon exercise of new common stock purchase warrants issued to institutional investors in connection with an October 17, 2025 private placement. These New Warrants have an exercise price of $0.54 per share and can only be exercised after stockholders approve the full issuance. If all New Warrants are exercised for cash, the company would receive up to approximately $8.7 million in gross proceeds, which it states could be important to funding operations.
The company notes that approval would significantly increase the number of shares outstanding over time, diluting existing ownership and potentially pressuring the stock price if the new shares are sold into the market. As of the December 31, 2025 record date, 33,845,042 shares of common stock were outstanding. Stockholders are also being asked to approve an adjournment proposal that would allow the meeting to be postponed to solicit additional votes if support for the warrant exercise is initially insufficient.
Theriva Biologics, Inc. reported that on December 15, 2025 it called to order a Special Meeting of Stockholders but could not convene the meeting because there were not enough shares present or represented by proxy to form a quorum. The company plans to call a new special meeting to seek approval of a warrant exercise proposal and an adjournment proposal described in a proxy statement filed on November 10, 2025, and will announce the new date and time and send updated proxy materials.
Under an Inducement Agreement dated October 16, 2025 with certain institutional investors, Theriva agreed to seek stockholder approval for the issuance of up to 16,184,560 shares of common stock upon exercise of newly issued common stock purchase warrants. Because the Special Meeting could not be convened, Theriva is obligated to call additional stockholder meetings every 60 days to seek this approval until it is obtained or the new warrants are no longer outstanding.
Theriva Biologics, Inc. is registering 16,184,560 shares of common stock for resale by existing investors, covering shares issuable upon exercise of “New Warrants” issued in an October 2025 warrant inducement transaction. Those investors had previously held warrants to buy 8,092,280 shares, which they agreed to exercise for cash at a reduced price of $0.54 per share. In return, Theriva issued New Warrants for 16,184,560 additional shares, also at $0.54 per share.
Theriva has already received approximately $4.4 million in gross proceeds from the exercised prior warrants, before fees. The company will not receive any proceeds from resale of the registered shares, but would receive cash only if holders exercise the New Warrants. Shares outstanding were 33,739,643 as of November 3, 2025, and would be 49,924,203 assuming full exercise of the New Warrants. The stock last closed at $0.2189 per share on the NYSE American under the symbol “TOVX.”
Theriva Biologics (TOVX) filed its Q3 2025 Form 10‑Q, reporting a net loss of $4.4 million for the quarter and $21.7 million year‑to‑date. Cash and cash equivalents were $7.5 million at September 30, 2025. Total liabilities rose to $24.1 million, while stockholders’ equity declined to $6.7 million.
The company disclosed substantial doubt about its ability to continue as a going concern without additional capital or strategic transactions. Management approved a restructuring on September 28, 2025, including a 32% workforce reduction (about seven employees), estimating $0.52 million in charges and anticipating ~$1.8 million of annual compensation savings. Management stated that $15.5 million of cash in early November 2025 is expected to fund operations through Q4 2026 and into Q1 2027.
Contingent consideration related to the VCN acquisition increased to $10.8 million, and an accrued milestone of $5.5 million is due to Grifols following VIRAGE Phase 2b endpoints; a $6 million payment was partially deferred. The quarter included financing cash inflows from a May 2025 public offering and ATM sales. Shares outstanding were 33,739,643 as of November 7, 2025.